Because AOD-9604 does not activate growth hormone receptors and functions through an entirely separate beta-3 adrenergic pathway, it does not trigger cortisol release
In the obese trial cohort, 1 mg moved 24-hour heart rate by +0.7 bpm in the first week, essentially placebo. In a healthy lean Phase 1b group, the same dose raised heart rate by about 10 bpm, with a peak near 15 to 20 bpm around days 4 to 6. Lean, younger participants had more reactive heart-rate control than the sedentary, obese, and metabolically stressed trial population
Get a Quote from top distributors
Luke's Hospital lists the following drugs as those that might possibly interact with B12 injections
Medical necessity : BCBS will likely require proof that Wegovy is medically necessary
Retatrutide is currently in Phase 2 clinical trials